Allen-Auerbach Martin, de Vos Sven, Czernin Johannes
Ahmanson Translational Imaging Division/Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-6948, USA.
Radiol Clin North Am. 2013 Sep;51(5):833-44. doi: 10.1016/j.rcl.2013.05.004. Epub 2013 Jul 9.
[¹⁸F]Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scans provide patients and referring physicians with diagnostic PET and CT information in a single imaging session. Because most lymphomas show high glucose metabolic activity and FDG avidity, they can be reliably assessed with FDG-PET/CT. PET/CT has emerged as the modality of choice for treatment strategy assessments in patients with lymphoma. Its ability to characterize masses as benign or malignant and its high sensitivity and specificity for staging, restaging, and treatment monitoring have led to widespread acceptance of PET imaging for managing patients with lymphoma.
[¹⁸F]氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）可在一次成像检查中为患者及转诊医生提供PET和CT诊断信息。由于大多数淋巴瘤表现出高葡萄糖代谢活性和FDG亲和力，因此可通过FDG-PET/CT进行可靠评估。PET/CT已成为淋巴瘤患者治疗策略评估的首选方式。它能够将肿块区分为良性或恶性，并且在分期、再分期及治疗监测方面具有高敏感性和特异性，这使得PET成像在淋巴瘤患者管理中得到广泛认可。
